Posted by Michael Wonder on 17 Jul 2026
Update on access to goserelin 3.6 mg implant (Zoladex Implant)
16 July 2026 - Further to its request to delist goserelin 3.6 mg implant (Zoladex Implant) from the PBS on 1 November 2026, AstraZeneca has advised that from 1 November 2026, patients will be able to access the 3.6 mg Zoladex Implant through the Zoladex Continuity Program.
Under this program, AstraZeneca will supply the medicine at no cost to eligible patients.
